Fundraising FoxBrandon Capital — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.
BiotechDeep TechHealthtechMunich, DE
Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in
Co-investorsBioqube VenturesJeito CapitalForbionBayern KapitalBioGeneration VenturesCanaan Partners+2 more
Biotechnology company enhancing vaccine performance with its HD-MAP high-density microarray skin-delivery platform, targeting infectious disease and oncology.
Co-investorsOneVenturesR&D Tax IncentiveTorrey Pines Investment
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Pheon Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.